Sugi Predict

Sugi Predict / Compounds / SCHEMBL318668

SCHEMBL318668

SCHEMBL318668

O=C1Nc2ccccc2C12CC2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 2/20 0.68
▸ OPRM1 P35372 1/20 0.56
▸ OPRK1 P41145 1/20 0.56
▸ OPRL1 P41146 1/20 0.56
▸ PDK2 Q15119 1/20 0.55
▸ PDK4 Q16654 1/20 0.55
▸ LMNA P02545 1/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ HTR1A P08908 4/20 0.51
▸ HTR2A P28223 4/20 0.51
▸ HTR7 P34969 4/20 0.51
▸ HTR6 P50406 4/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ PGR P06401 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ TNKS O95271 1/20 0.47
▸ TNKS2 Q9H2K2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29622026 1.00 BACE1 (0.68) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL1268479 0.92 BACE1 (0.64) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL29609089 0.92 BACE1 (0.64) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL29387092 0.92 BACE1 (0.64) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL2265580 0.92 BACE1 (0.64) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL25233667 0.91 BACE1 (0.58) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL21537944 0.90 BACE1 (0.62) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL1223213 0.90 BACE1 (0.62) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL29799132 0.90 BACE1 (0.62) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL788678 0.88 BACE1 (0.81) BACE1OPRM1OPRK1OPRL1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4065575-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2024-01-31 — — EP claimed
CN-104098507-A Oxindole spiro-cyclopropane derivative and synthetic method thereof UNIV TAIYUAN TECHNOLOGY 2014-10-15 — — CN claimed
WO-2026103873-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 杭州百新生物医药科技有限公司 2026-05-21 — — WO disclosed
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS INC (US) 2026-04-23 — — US disclosed
US-20260085077-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2026-03-26 — — US disclosed
US-20250270174-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. 2025-08-28 — — US disclosed
EP-4583977-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-07-16 — — EP disclosed
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-05-29 — — US disclosed
WO-2025092818-A1 PYRIDINE DERIVATIVE AND USE THEREOF IN MEDICINE 康百达（四川）生物医药科技有限公司 2025-05-08 — — WO disclosed
EP-4540240-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 — — EP disclosed
US-20240425474-A1 VINYL THIANTHRENIUM COMPOUND, PROCESS FOR ITS PREPARATION AND ITS USE FOR TRANSFERRING A VINYL GROUP STUDIENGESELLSCHAFT KOHLE GGMBH (DE) 2024-12-26 — — US disclosed
WO-2006029861-A1 THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-23 — — WO disclosed
WO-2006023107-A1 PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF WYETH (US) 2006-03-02 — — WO disclosed
US-20060030615-A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof WYETH (US) 2006-02-09 — — US disclosed
US-5399562-A 5-hydroxytryptamine agonists or antagonists; gastrointestinal disorders G. D. SEARLE & CO. (US) 1995-03-21 — — US disclosed
EP-0381374-A1 Phosphodiesterase inhibitors LES LABORATOIRES BEECHAM S.A. (FR) 1990-08-08 — — EP disclosed
US-4933336-A Thiadiazinone, oxadiazinone and triazinone derivatives, and their use for treating acute or chronic heart disease LABORATOIRES SOBIO S.A. (FR) 1990-06-12 — — US disclosed
EP-0178876-B1 PYRIDAZINONE INOTROPIC AGENTS ELI LILLY AND COMPANY (US) 1989-09-06 — — EP disclosed
US-4617302-A Inotropic agents ELI LILLY AND COMPANY (US) 1986-10-14 — — US disclosed
EP-0178876-A1 Pyridazinone inotropic agents ELI LILLY AND COMPANY (US) 1986-04-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 BACE1 3882/4885OPRM1 1125/4885OPRK1 337/4885
US-20240425474-A1 VINYL THIANTHRENIUM COMPOUND, PROCESS FOR ITS PREPARATION AND ITS USE FOR TRANSFERRING A VINYL GROUP TRRAP, TST, TERB1 BACE1 2123/4885OPRM1 2154/4885OPRK1 2041/4885
US-20260085077-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS TYK2, JAK1, JAK3 BACE1 4552/4885OPRM1 403/4885OPRK1 96/4885
US-20250270174-A1 CD73 COMPOUNDS ENTPD5, NT5E, ENTPD1 BACE1 896/4885OPRM1 1679/4885OPRK1 1766/4885
US-20060030615-A1 Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof PGR, PGRMC2, PGRMC1 BACE1 4758/4885OPRM1 65/4885OPRK1 59/4885
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 BACE1 1898/4885OPRM1 4240/4885OPRK1 2024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.